De Novo device
Parathyroid Detection (Model PTeye) System
Aibiomed, Corp. · Parathyroid Autofluorescence Detection Device (QDF, Class II) · First FDA decision Nov 2, 2018, newest Nov 2, 2018Thyroid nodules and thyroid disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
50
Naming "Parathyroid"
MAUDE reports
84
Brand "Parathyroid", since 2015
PubMed studies
58,482
Mentioning "Parathyroid"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Parathyroid Detection (Model PTeye) System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Parathyroid Detection (Model PTeye) SystemNew device typeDe Novo
DEN170056 · Decided Nov 2, 2018 · 403 days after receipt
Device type: Parathyroid Autofluorescence Detection Device (QDF) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Parathormone (Parathyroid Hormone)Local determinationIn effectL34018First Coast Service Options, Inc.Updated Nov 5, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "Parathyroid", any status and sponsor, newest update first.
- NIRAF-Guided Parathyroid Identification During ThyroidectomyPivotal-lookingRecruiting
Ss. Cyril and Methodius University of SkopjeAcademic, hospital or other
NCT07617584 · 280 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 1, 2029
Device: Wearable Near-Infrared Autofluorescence Imaging System · For: Hypocalcemia; Hypoparathyroidism; Thyroid Diseases and 3 more
Sites: Skopje, North Macedonia
- Treating PHPT With the nPulse™ Vybrance™ PE SystemNot yet recruiting
Pulse Biosciences, Inc.Not on our public-company list
NCT07912892 · 15 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2027
Device: Ultrasound-Guided Parathyroid Nanosecond Pulsed Field Ablation (nsPFA) · For: Primary Hyperparathyroidism
Sites: Sarasota, Florida
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT07444723 · 193 participants (planned) · Start Apr 16, 2026 · Primary completion Feb 5, 2035
Device: NeuroEXPLORER · For: Primary Hyperparathyroidism; Parathyroid Cancer; Multiple Endocrine Neoplasias and 2 more
Sites: Bethesda, Maryland
47 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Parathyroid", and for the whole product code for context.
This brand
84 reports: 84 malfunction, 0 injury, 0 death
Whole product code QDF
3 reports: 3 malfunction, 0 injury, 0 death
Newest reports for this brand
- Atellica IM Intact Parathyroid Hormone (PTH)Malfunction
Siemens Healthcare Diagnostics, Inc.
1219913-2026-00169 · Received Aug 25, 2026 · Event dated Jul 14, 2026
Device type: Radioimmunoassay, Parathyroid Hormone (CEW)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Atellica IM Intact Parathyroid Hormone (PTH)Malfunction
Siemens Healthcare Diagnostics, Inc.
1219913-2026-00165 · Received Aug 24, 2026 · Event dated Jun 24, 2026
Device type: Radioimmunoassay, Parathyroid Hormone (CEW)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ATELLICA IM INTACT PARATHYROID HORMONE (PTH)Malfunction
SIEMENS HEALTHCARE DIAGNOSTICS INC.
1219913-2024-00006 · Received Jan 17, 2024 · Event dated Dec 20, 2023
Device type: Radioimmunoassay, Parathyroid Hormone (CEW)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Parathyroid"[tiab]. The summary above synthesizes these.
- Parathyroid Pathology.
Guilmette J, Sadow PM · Surg Pathol Clin · 2019Review
- Parathyroid hormone.
Leung EKY · Adv Clin Chem · 2021
- Intrathyroidal Parathyroid Adenoma.
Zouggari S, Bsiss MA, Matrane A, et al. · Mol Imaging Radionucl Ther · 2024
- Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA, Mete O, Juhlin CC, et al. · Endocr Pathol · 2022Review
- Pediatric parathyroid disease.
Jamshidi R, Egan JC · Semin Pediatr Surg · 2020Review
- Editorial: 2023 symposium on parathyroid fluorescence.
Di Meglio I, Balasubramanian SP, Cha RJ, et al. · Front Endocrinol (Lausanne) · 2024Editorial, Introductory Journal Article
- Parathyroid Tumor Microenvironment.
Verdelli C, Vaira V, Corbetta S · Adv Exp Med Biol · 2020Review
- Parathyroid cysts.
Clark OH · Am J Surg · 1978Research Support, U.S. Gov't, Non-P.H.S.
- Metabolism of parathyroid organoids.
Sekhar KR, Codreanu SG, Williams OC, et al. · Front Endocrinol (Lausanne) · 2023Research Support, Non-U.S. Gov't
- Parathyroid autotransplantation.
Giuliani L, Carmignani G, Belgrano E, et al. · Eur Urol · 1981
- Update in Parathyroid Imaging.
Kuzminski SJ, Sosa JA, Hoang JK · Magn Reson Imaging Clin N Am · 2018Review
- Parathyroid Tumors: Molecular Signatures.
Marini F, Giusti F, Iantomasi T, et al. · Int J Mol Sci · 2021Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.